InsiderTrades.com logo

Masaru Matsuda Biography and Net Worth

General Counsel of Arcutis Biotherapeutics
  • Phone
  • Email
  • Website


Mr Matsuda joined Arcutis in January 2022 as general counsel and corporate secretary. He is responsible for all legal and compliance for the company, as well as serving as secretary of the board of directors. Mr Matsuda previously served as senior vice president, general counsel, chief compliance officer, and corporate secretary at Halozyme Therapeutics, Inc. Prior to Halozyme, Mr Matsuda worked at Amgen for 18 years in positions of increasing responsibility with his last role serving as vice president, Law, Global Commercial Operations, where he was responsible for strategic commercial legal support to the US Commercial Operations organization, as well as Medical Affairs, Compliance, Global Value, Access & Policy, Global Marketing, and Biosimilars divisions. Mr Matsuda received a Bachelor of Science in Business Administration with a dual emphasis in Corporate Finance and International Finance from the University of Southern California, and a Juris Doctorate from University of California, Hastings College of the Law.

What is Masaru Matsuda's net worth?

The estimated net worth of Masaru Matsuda is at least $2.61 million as of February 3rd, 2025. Mr. Matsuda owns 178,692 shares of Arcutis Biotherapeutics stock worth more than $2,612,477 as of March 15th. This net worth evaluation does not reflect any other investments that Mr. Matsuda may own. Additionally, Mr. Matsuda receives a salary of $626,220.00 as General Counsel at Arcutis Biotherapeutics. Learn More about Masaru Matsuda's net worth.

How old is Masaru Matsuda?

Mr. Matsuda is currently 53 years old. There are 6 older executives and no younger executives at Arcutis Biotherapeutics. The oldest executive at Arcutis Biotherapeutics is Dr. Bhaskar Chaudhuri Ph.D., Co-Founder & Independent Director, who is 69 years old. Learn More on Masaru Matsuda's age.

What is Masaru Matsuda's salary?

As the General Counsel of Arcutis Biotherapeutics, Inc., Mr. Matsuda earns $626,220.00 per year. There are 3 executives that earn more than Mr. Matsuda. The highest earning executive at Arcutis Biotherapeutics is Mr. Todd Franklin Watanabe M.A., President, CEO & Director, who commands a salary of $1,010,000.00 per year. Learn More on Masaru Matsuda's salary.

How do I contact Masaru Matsuda?

The corporate mailing address for Mr. Matsuda and other Arcutis Biotherapeutics executives is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. Arcutis Biotherapeutics can also be reached via phone at 805-418-5006 and via email at ir@arcutis.com. Learn More on Masaru Matsuda's contact information.

Has Masaru Matsuda been buying or selling shares of Arcutis Biotherapeutics?

During the last ninety days, Masaru Matsuda has sold $105,892.60 of Arcutis Biotherapeutics stock. Most recently, Masaru Matsuda sold 8,338 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $12.70, for a transaction totalling $105,892.60. Following the completion of the sale, the insider now directly owns 178,692 shares of the company's stock, valued at $2,269,388.40. Learn More on Masaru Matsuda's trading history.

Who are Arcutis Biotherapeutics' active insiders?

Arcutis Biotherapeutics' insider roster includes Patrick Burnett (Insider), Scott Burrows (CFO), Bhaskar Chaudhuri (Director), Terrie Curran (Director), Larry Edwards (Insider), Masaru Matsuda (General Counsel), David Topper (CFO), Patricia Turney (SVP), Todd Watanabe (CEO), and Howard Welgus (Director). Learn More on Arcutis Biotherapeutics' active insiders.

Are insiders buying or selling shares of Arcutis Biotherapeutics?

During the last year, Arcutis Biotherapeutics insiders bought shares 1 times. They purchased a total of 1,093 shares worth more than $7,771.23. During the last year, insiders at the sold shares 25 times. They sold a total of 204,162 shares worth more than $2,214,551.74. The most recent insider tranaction occured on March, 3rd when insider Patrick Burnett sold 2,819 shares worth more than $36,731.57. Insiders at Arcutis Biotherapeutics own 9.5% of the company. Learn More about insider trades at Arcutis Biotherapeutics.

Information on this page was last updated on 3/3/2025.

Masaru Matsuda Insider Trading History at Arcutis Biotherapeutics

See Full Table

Masaru Matsuda Buying and Selling Activity at Arcutis Biotherapeutics

This chart shows Masaru Matsuda's buying and selling at Arcutis Biotherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$106ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100k-$50k$0$50k$100kTotal Insider BuyingTotal Insider Selling

Arcutis Biotherapeutics Company Overview

Arcutis Biotherapeutics logo
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Read More

Today's Range

Now: $14.62
Low: $14.51
High: $15.38

50 Day Range

MA: $13.52
Low: $11.40
High: $15.76

2 Week Range

Now: $14.62
Low: $6.99
High: $16.20

Volume

1,689,885 shs

Average Volume

2,433,515 shs

Market Capitalization

$1.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48